Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer

Japanese Journal of Clinical Oncology

Volumn 42, Issue 2, 2012, Pages 105-112

  Sakamoto, Hiroki ^a   Kimura, Hideharu ^a   Sekijima, Masaru ^b   Matsumoto, Kazuko ^a   Arao, Tokuzo ^a   Chikugo, Takaaki ^a   Yamada, Yasuhide ^c   Kitano, Masayuki ^a   Ito, Akihiko ^a   Takeyama, Yoshifumi ^a   Kudo, Masatoshi ^a   Nishio, Kazuto ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Angiogenesis; IL 8; Pancreatic cancer; Plasma

Indexed keywords

ANGIOGENESIS RELATED MOLECULE; ANGIOPOIETIN 2; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; FOLLISTATIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 8; LEPTIN; PEPTIDES AND PROTEINS; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HEPATOBILIARY DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREATITIS; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-2; ANTIGENS, CD31; BILIARY TRACT DISEASES; FEMALE; FOLLISTATIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERLEUKIN-8; KAPLAN-MEIER ESTIMATE; LEPTIN; LIVER DISEASES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-SIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856608936     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr178     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Folkman J. Addressing tumor blood vessels. Nat Biotechnol 1997;15:510-1.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
4. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009;59:111-37.
5. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-40.
6. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617-22.
7. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-7.
8. Spano J-P, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008;371:2101-8.
9. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Büchler MW, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997;3:1309-16.
10. Fujimoto K, Hosotani R, Wada M, Lee JU, Koshida T, Miyamoto Y, et al. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 1998;34:1439-47.
11. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88:2239-45.
12. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999;79:1553-63.
13. Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A, et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002;25:122-9.
14. Kobayashi A, Yamaguchi T, Ishihara T, Ohshima T, Baba T, Shirai Y, et al. Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma. Pancreas 2005;31:74-8.
15. Karayiannakis AJ, Bolanaki H, Syrigos KN, Asimakopoulos B, Polychronidis A, Anagnostoulis S, et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 2003;194:119-24.
16. Yamada Y, Arao T, Matsumoto K, Gupta V, Tan W, Fedynyshyn J, et al. Plasma concentrations of VCAM-1 and PAI-1: a predictive biomarker for post-operative recurrence in colorectal cancer. Cancer Sci 2010;101:1886-90.
17. Kimura H, Kasahara K, Sekijima M, Tamura T, Nishio K. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. Lung Cancer 2005;50:393-9.
18. Kemik O, Purisa S, Kemik AS, Tuzun S. Increase in the circulating level of hepatocyte growth factor in pancreatic cancer patients. Bratisl Lek Listy 2009;110:627-9.
19. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma. Cancer 2004;101:2727-36.
20. Chang YT, Chang MC, Wei SC, Tien YW, Hsu C, Liang PC, et al. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 2008;37:145-50.
21. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001;12:375-91.
22. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-41.
23. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999;5:3711-21.